Trial comparing treatments for Small Cell Lung Cancer Extensive Stage
Official title BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01)
ClinicalTrials.gov ID: NCT07625644
What this study is testing
What is BL-M14D1 and Atezolizumab?
BL-M14D1 and Atezolizumab is an investigational medicine, given as an infusion into a vein, being studied as a potential treatment for small cell lung cancer extensive stage.
Also referred to as BL-M14D1, Atezolizumab.
Plain-language explanation of the investigational treatment - it is being studied and is not an approved or proven therapy. The study team can confirm the details.
- What it's testing
- The objective of the study is to evaluate the efficacy and safety of BL-M14D1 in combination with Atezolizumab compared to Standard-of-Care Therapy in adult participants with previously untreated extensive-stage small cell lung cancer (ES-SCLC).
- Phase 3: a large, late-stage study
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 18 and older
You may be able to join if
- Histologically or cytologically confirmed first-line (1L), extensive-stage (ES) small cell lung cancer (SCLC)
- Must be eligible to receive a platinum-based chemotherapy regimen in combination with an anti-PD-L1 inhibitor.
- At least one measurable lesion based on RECIST v1.1 per investigator assessment.
- An Eastern Cooperative Oncology Group performance status (ECOG PS) of 0 to 1.
- Adequate organ function
You likely can't join if
- Received any kind of platinum or etoposide treatment for limited stage (LS) SCLC within 6 months prior to enrollment.
- Participants who have received prior topoisomerase inhibitor-based ADC therapy.
- Participants with history of severe heart disease
- Participants with active autoimmune diseases and inflammatory diseases,
- Participants with other prior or concurrent malignancies except for basal cell carcinoma of the skin, squamous cell carcinoma of the skin and/or...
- Other protocol-defined inclusion/exclusion criteria apply.
The study team makes the final eligibility decision.
Where it's taking place
- Springdale, Arkansas, United States
- Glendale, California, United States
- Long Beach, California, United States
- Los Angeles, California, United States
- Miami, Florida, United States
- East Brunswick, New Jersey, United States
- Fairfax, Virginia, United States
- Garran, Australian Capital Territory, Australia
- Southport, Queensland, Australia
- Bedford Park, South Australia, Australia
- Gabrovo, Bulgaria
- Pleven, Bulgaria
- Plovdiv, Bulgaria
- Sofia, Bulgaria
- Calgary, Alberta, Canada
- Greenfield Park, Quebec, Canada
- České Budějovice, Czechia
- Ostrava, Czechia
- Ostrava-Poruba, Czechia
- Créteil, France
+ 30 more site(s).
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Springdale, Arkansas, United States; Glendale, California, United States; Long Beach, California, United States; Los Angeles, California, United States; Miami, Florida, United States; East Brunswick, New Jersey, United States and 44 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.